189 related articles for article (PubMed ID: 18301060)
21. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
22. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
23. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
[TBL] [Abstract][Full Text] [Related]
24. [Protective role of antiretroviral treatment in the impairment of renal function in a cohort of human immunodeficiency virus patients].
Mérida L; de la Torre J; Olalla J; Noureddine M; del Arco A; Prada JL; Aguilar A; García-Alegría J
Med Clin (Barc); 2011 Jun; 137(3):104-7. PubMed ID: 21397277
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.
Wohl DA; Zeng D; Stewart P; Glomb N; Alcorn T; Jones S; Handy J; Fiscus S; Weinberg A; Gowda D; van der Horst C
J Acquir Immune Defic Syndr; 2005 Apr; 38(5):538-44. PubMed ID: 15793363
[TBL] [Abstract][Full Text] [Related]
27. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
Guaraldi G; Roverato A; Giovanardi C; Ravera F; Squillace N; Orlando G; Cappelli G; Esposito R; Palella F
J Antimicrob Chemother; 2009 Feb; 63(2):374-9. PubMed ID: 19095683
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E; Palmisano L; Sarmati L; D'Ettorre G; Parisi S; Andreotti M; Buonomini A; Pirillo FM; Narciso P; Bellagamba R; Vullo V; Montano M; Di Perri G; Andreoni M
Curr HIV Res; 2008 May; 6(3):261-6. PubMed ID: 18473790
[TBL] [Abstract][Full Text] [Related]
29. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
30. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
31. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
[TBL] [Abstract][Full Text] [Related]
32. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.
Tenorio AR; Smith KY; Kuritzkes DR; Sha BE; Donoval B; Young R; Jennings C; Bremer J; Shott S; Landay A; Kessler HA
J Acquir Immune Defic Syndr; 2003 Dec; 34(5):491-6. PubMed ID: 14657759
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
[TBL] [Abstract][Full Text] [Related]
34. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
[TBL] [Abstract][Full Text] [Related]
35. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
[TBL] [Abstract][Full Text] [Related]
36. Chronic renal failure among HIV-1-infected patients.
Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
[TBL] [Abstract][Full Text] [Related]
37. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
38. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
[TBL] [Abstract][Full Text] [Related]
39. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
40. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
